Journal article
Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration
F Abedi, S Wickremasinghe, AJ Richardson, AFM Islam, RH Guymer, PN Baird
Ophthalmology | Published : 2013
Abstract
Purpose: To determine the association of genetic variants in known age-related macular degeneration (AMD) risk-associated genes with outcome of anti-vascular endothelial growth factor (VEGF) treatment in neovascular AMD. Design: Prospective cohort study. Participants: We enrolled 224 consecutive patients with neovascular AMD at the Royal Victorian Eye and Ear Hospital, Australia. Methods: Patients were treated with 3 initial monthly ranibizumab or bevacizumab injections followed by 9 months of "as required" injections based on clinician's decision at each follow-up visit according to retreatment criteria. Seventeen single nucleotide polymorphisms (SNPs) in known AMD risk-associated genes inc..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
Funded by the National Health and Medical Research Council (NHMRC) project grants 590205 and 1008979, an NHMRC- Clinical Research Excellence grant 529923 - Translational Clinical Research in Major Eye Diseases, NHMRC practitioner fellowship 529905 (R.H.G.), NHMRC Senior Research Fellowship 1028444 (P.N.B.), and the Macular Vision Loss Support Society of Australia. The Centre for Eye Research Australia (CERA) receives Operational Infrastructure Support from the Victorian Government. The sponsor or funding organizations had no role in the design or conduct of this research.